Drug Combo Proves Powerful Against Lung Cancer Lancaster NY

A two-drug combination treatment in Lancaster proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

STEVEN AMBRUSKO, MD
(412) 878-7349
219 Bryant Street
Buffalo, NY
JAMES CONWAY, MD
(716) 630-1039
295 Essjay Road
Buffalo, NY
BRIAN MCGRATH, MD
(716) 859-1531
100 High Street
Buffalo, NY
Michael Carol Snyderman, MD
716-828-2495
565 Abbott Rd
Buffalo, NY
Thomas Patrick O'Connor, MD
716-677-5100
Western NY Med Park 550 Orchard Park Rd
Buffalo, NY
THOMAS OCONNOR, MD
(716) 447-6100
2950 Elmwood Avenue
Buffalo, NY
ROBERT ZIELINSKI, MD
(716) 630-1059
295 Essjay Road
Buffalo, NY
FOONG MING LAM, MD
(716) 626-3033
300 International Drive
Buffalo, NY
Nithya Ramnath, MD
716-845-3099
Elm and Carlton St
Buffalo, NY
Tallal Hussein Younis, MD
Buffalo, NY
Data Provided by:
  

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Lancaster NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Fungal Infection Treatments Lancaster NY
- Exercise for Prostate Cancer Lancaster NY
- Delayed Prostate Cancer Therapy Lancaster NY
- Risks for Childhood Cancer Survivors Lancaster NY
- Genetic Clues for Skin Cancer Therapies Lancaster NY
- Hormone Therapy for Breast Cancer Lancaster NY
- Hormone Therapy for Lung Cancer Lancaster NY
- Exercise for Breast Cancer Survival Lancaster NY